This month there have been a number of changes at the head of organizations working on biosimilars and the advanced therapeutic space.
Research and expenditure into cell and gene therapies have only increased in recent years, as the first products have reached the market. This is reflected in several appointments this month at the heads of organization and companies working in the space.
The success of the UK, in particular, has seen figureheads within the space grow in importance, leading to the new head of the most prominent accelerator organization.
During this period, the UK’s biosimilar industry body has also bolstered its leadership, coming at a time when uptake of the medicines is beginning to create significant savings for the country.